Valategrast

Drug Profile

Valategrast

Alternative Names: R-411; Ro0272441/002; Ro27-2441; Ro27-2441/002

Latest Information Update: 01 Apr 2008

Price : $50

At a glance

  • Originator Roche
  • Class Antiasthmatics
  • Mechanism of Action Alpha4-beta7 integrin antagonists; Integrin alpha4beta1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Multiple sclerosis
  • Discontinued Asthma

Most Recent Events

  • 19 Oct 2006 Discontinued - Phase-II for Asthma in Europe (PO)
  • 19 Oct 2006 Discontinued - Phase-I for Asthma in USA (PO)
  • 17 Oct 2006 Phase-I clinical trials in Multiple sclerosis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top